Skip to main content

Sunmax

MaterialsTaiwanFounded 2001· One of 955 Materials companies tracked by AMPulse

Develops high-standard collagen-based medical devices and bioprinting materials for tissue regeneration.

CEO / Founder
Lin Ming-Yi (林明毅)
Team Size
51-200
Stage
Active
Total Funding
$17M
Latest Round
Post-IPO
Key Investors
Publicly traded (TPEx: 4728); Institutional investors in Taiwan

Technology & Products

Key Products

Collagen dermal fillers, bone grafts & dental membranes, facial masks, essence creams, eye creams, and other collagen-based medical devices and bioprinting materials.

Technological Advantage

Enables the creation of 3D printed scaffolds for tissue engineering using liquid collagen inks that maintain biological integrity during the printing process.

Differentiation

Value Proposition

Provides pig-based collagen (Porcogen) that remains liquid pre-fibrillized, enabling high-precision 3D printing of scaffolds for artificial tissues and cell culture with improved biological integrity.

How They Differentiate

Proprietary SPF (Specific Pathogen Free) porcine collagen extraction achieves 99.9% purity, offering higher thermal stability and lower immunogenicity compared to traditional bovine-derived collagen or tobacco-based rhCollagen (CollPlant).

Market & Competition

Target Customers

Aesthetic medicine clinics, orthopedic surgeons, and regenerative medicine researchers requiring medical-grade collagen bio-inks for tissue engineering.

Industry Verticals

Medical; Biotechnology

Competitors

Maxigen Biotech Inc., Tcm Biotech International, Dv Biomed Co

Growth & Milestones

Growth Metrics

Sales grew to TWD 1,752.89 million in 2025 from 1,262.82 million in the prior year; net income reached TWD 209.78 million (data for related Sun Max Tech entity).

Major Milestones

Founded in 2001; Publicly listed in Taiwan since at least 2017; Developed Porcogen pig-based collagen for bioprinting

Notable Customers

National Taiwan University Hospital; Taipei Veterans General Hospital; Various Tier-1 aesthetic clinics in Mainland China and Taiwan

https://www.sunmaxbiotech.com

Why this company matters

Sunmax develops collagen-based medical devices and bioprinting materials, focusing on tissue regeneration. Its core differentiator is Porcogen, a pig-derived collagen that remains liquid before fibrillization, enabling high-precision extrusion-based bioprinting (MEX) of scaffolds. The company claims 99.9% purity via proprietary SPF porcine extraction, offering higher thermal stability and lower immunogenicity than bovine collagen or tobacco-based rhCollagen from CollPlant.

Products span collagen dermal fillers, bone grafts, dental membranes, and cosmetic creams, but the strategic growth area is bio-inks for 3D printed tissue constructs. Target customers include aesthetic medicine clinics, orthopedic surgeons, and regenerative medicine researchers. Notable clinical partners include National Taiwan University Hospital and Taipei Veterans General Hospital, with distribution reaching tier-1 aesthetic clinics in China and Taiwan.

Sunmax is publicly traded on the Taipei Exchange (TPEx: 4728) and has raised $17 million in funding. Sales for a related entity reached TWD 1,752.89 million in 2025, up from TWD 1,262.82 million the prior year. Key competitors include Maxigen Biotech, Tcm Biotech International, and Dv Biomed Co. A strategic partnership with Bloomage Biotech supports distribution, while research collaboration with National Cheng Kung University advances bioprinting applications.

The company's moat lies in its proprietary porcine collagen extraction process and the Porcogen formulation optimized for bioprinting. However, competition from recombinant collagen producers (e.g., CollPlant) and synthetic polymer scaffolds could limit adoption. Sunmax's ability to scale bio-ink production for clinical and commercial tissue engineering will determine its long-term position.